Kdr - kinase insert domain protein receptor Gene

Mus musculus

Also known as orv; Flk1; Ly73; Flk-1; Krd-1; VEGFR2; VEGFR-2; sVEGFR-2; 6130401C07

Gene ID: 16542 | Gene type: protein coding

About Kdr

Chromosome 5: 76,093,487-76,139,118 reverse strand.GRCm39:CM000998.3

This gene has 3 transcripts (splice variants), 199 orthologues, 53 paralogues and is associated with 30 phenotypes. Broad expression in lung adult (RPKM 42.4), heart adult (RPKM 19.3) and 22 other tissues.

Summary

Enables growth factor binding activity and vascular endothelial growth factor-activated receptor activity. Involved in several processes, including circulatory system development; peptidyl-tyrosine autophosphorylation; and positive regulation of vasculogenesis. Acts upstream of or within several processes, including animal organ development; positive regulation of cell population proliferation; and vasculature development. Located in several cellular components, including cell junction; endosome; and external side of plasma membrane. Is expressed in several structures, including alimentary system; cardiovascular system; central nervous system; extraembryonic component; and genitourinary system. Human ortholog(s) of this gene implicated in several diseases, including adhesions of uterus; artery disease (multiple); gastrointestinal system Cancer (multiple); macular degeneration (multiple); and pancreatic Cancer (multiple). Orthologous to human VEGFR2/KDR/Flk-1 (kinase insert domain receptor). [provided by Alliance of Genome Resources, Apr 2022]

Kdr Products(6)

mRNA	Protein	Name
NM_001403141.1	NP_001390070.1	vascular endothelial growth factor receptor 2 isoform 1 precursor
NM_001403144.1	NP_001390073.1	vascular endothelial growth factor receptor 2 isoform 5
NM_001363216.1	NP_001350145.1	vascular endothelial growth factor receptor 2 isoform 2 precursor
NM_001403143.1	NP_001390072.1	vascular endothelial growth factor receptor 2 isoform 4 precursor
NM_001403142.1	NP_001390071.1	vascular endothelial growth factor receptor 2 isoform 3 precursor
NM_010612.3	NP_034742.2	vascular endothelial growth factor receptor 2 isoform 1 precursor

Kdr Protein Structure

Ig_3

I-set

VEGFR-2_TMD

PTKc_VEGFR2

0
300
600
900
1200
1345 a.a.

Protein Preferred Names

Protein Names

vascular endothelial growth factor receptor 2

VEGF receptor-2	fetal liver kinase 1
kinase NYK	protein-tyrosine kinase receptor flk-1
soluble vascular endothelial growth factor receptor 2	vascular endothelial growth factor receptor-3

Recombinant Kdr Proteins

Cat. No.	Product Name	Accession	Purity
HY-P72429	VEGFR-2 Protein, Mouse (743a.a, HEK293, Fc)	P35918 (A20-E762)	≥95%
HY-P73480	VEGFR-2 Protein, Mouse (762a.a, HEK293, Fc)	P35918 (M1-E762)	≥95%
HY-P74471	VEGFR-2 Protein, Mouse (HEK293, His)	P35918 (M1-E762)	≥95%
HY-P74472	VEGFR-2 Protein, Mouse (Biotinylated, HEK293, His)	P35918 (M1-E762)	≥95%

Related Agents

Approval

Bioactive Molecules (7)

Cat. No.	Product Name	Effect	Purity	Rare Diseases
HY-10260	Vandetanib		99.95%	Yes
HY-112306	Ripretinib		99.33%	Yes
HY-10330A	Toceranib phosphate	Inhibitor	98.54%	Unkown
HY-14914	Azilsartan		99.51%	Unkown
HY-10330	Toceranib	Inhibitor	96.86%	Unkown
HY-10260B	Vandetanib hydrochloride		/	Unkown
HY-10260A	Vandetanib trifluoroacetate		/	Unkown

Clinical Phase

Bioactive Molecules (13)

Cat. No.	Product Name	Effect	Purity	Phase
HY-50751	Linifanib		99.28%	Phase 3
HY-10205	Cediranib		99.58%	Phase 3
HY-13314	Tesevatinib	Inhibitor	99.21%	Phase 3
HY-12018	Vatalanib dihydrochloride		99.91%	Phase 3
HY-13049	Cediranib maleate		99.95%	Phase 3
HY-10203	Vatalanib	Inhibitor	99.86%	Phase 3
HY-50751G	Linifanib (GMP)	Inhibitor	/	Phase 3
HY-10374	Semaxinib	Inhibitor	99.96%	Phase 2
HY-10338	Foretinib	Inhibitor	99.77%	Phase 2
HY-13024	Rebastinib		99.91%	Phase 2
HY-10987A	ENMD-2076		99.12%	Phase 2
HY-10987	ENMD-2076 Tartrate		99.42%	Phase 2
HY-10204	OSI-930		98.57%	Phase 1

Inhibitory Antibodies (2)

Cat. No.	Product Name	Effect	Purity	Phase
HY-P99830	Conbercept		/	Phase 4
HY-P99768	Olinvacimab	Inhibitor	95.00%	Phase 2

Pre-clinical Phase

Bioactive Molecules (32)

Cat. No.	Product Name	Effect	Purity	Rare Diseases
HY-12299	WH-4-023	Inhibitor	99.75%	Unkown
HY-151361	AMPK-IN-3	Inhibitor	98.51%	Unkown
HY-W062835	CGP77675	Inhibitor	99.00%	Unkown
HY-13561	AZM475271	Inhibitor	99.85%	Unkown
HY-13838	PLX647	Inhibitor	99.79%	Unkown
HY-132135	(1E)-CFI-400437 dihydrochloride	Inhibitor	98.89%	Unkown
HY-100315	Tyrosine kinase-IN-1	Inhibitor	99.34%	Unkown
HY-133551	WF-47-JS03	Inhibitor	99.63%	Unkown
HY-15769	WHI-P180	Inhibitor	99.62%	Unkown
HY-101219	VEGFR-IN-1		98.42%	Unkown
HY-13785	ZM 306416	Inhibitor	99.80%	Unkown
HY-18302	c-Kit-IN-5-1	Inhibitor	98.16%	Unkown
HY-10517A	(Z)-Orantinib	Inhibitor	99.02%	Unkown
HY-119757	Tyrphostin AG1433	Inhibitor	99.08%	Unkown
HY-125741	GW768505A free base	Inhibitor	98.66%	Unkown
HY-10260S	Vandetanib-d6		/	Unkown
HY-10260S1	Vandetanib-d4		/	Unkown
HY-110272	Vatalanib succinate	Inhibitor	/	Unkown
HY-120214	TAS05567	Inhibitor	/	Unkown
HY-13838A	PLX647 dihydrochloride	Inhibitor	/	Unkown
HY-14979A	ML786 dihydrochloride	Inhibitor	/	Unkown
HY-15814	HG-7-85-01		99.94%	Unkown
HY-18318	Takeda-6D	Inhibitor	/	Unkown
HY-RS07226	KDR Human Pre-designed siRNA Set A		/	Unkown
HY-RS07227	Kdr Mouse Pre-designed siRNA Set A		/	Unkown
HY-RS07228	Kdr Rat Pre-designed siRNA Set A		/	Unkown
HY-W062835A	CGP77675 hydrate	Inhibitor	/	Unkown
HY-10330S	Toceranib-d8	Inhibitor	/	Unkown
HY-119757A	Tyrphostin AG1433 hydrochloride	Inhibitor	/	Unkown
HY-12018A	Vatalanib hydrochloride	Inhibitor	/	Unkown
HY-15769A	WHI-P180 hydrochloride	Inhibitor	/	Unkown
HY-101628	VEGFR-2-IN-9	Inhibitor	/	Unkown

Orthologs Information

Species	Symbol	Source	ID
Homo sapiens	Kdr	NCBI	NCBI:3791
Rattus norvegicus	Kdr	NCBI	NCBI:25589
Macaca mulatta	Kdr	NCBI	NCBI:698293

Name
Email *

	Sorry, but the email address you supplied was invalid.